about
Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data.Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension.Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.Considerations in glaucoma therapy: fixed combinations versus their component medications.Economic impact of primary open-angle glaucoma in Australia.Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management.A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertensionFixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.Volumetric and cost evaluation study of glaucoma medical therapy.Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma.Longitudinal trends in resource use in an incident cohort of open-angle glaucoma patients: resource use in open-angle glaucomaRole of early trabeculectomy in primary open-angle glaucoma in the developing world.Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for GlaucomaCost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model.Pharmacogenetics of ophthalmic topical beta-blockers.Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and SwedenFirst-year treatment costs among new initiators of topical prostaglandin analogs.Impact of patient access to Internet health records on glaucoma medication: randomized controlled trial.A comparison of measures used to describe adherence to glaucoma medication in a randomised controlled trial.Comparison of United States and canadian glaucoma medication costs and price change from 2006 to 2013.Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.The role of benzalkonium chloride in the occurrence of punctate keratitis: a meta-analysis of randomized, controlled clinical trials.Topical glaucoma therapy cost in Mexico.Difference in patterns of retinal ganglion cell damage between primary open-angle glaucoma and non-arteritic anterior ischaemic optic neuropathy.Direct healthcare costs of glaucoma treatment.Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema.
P2860
Q31141723-1107D940-8A57-4FFA-B42A-C0410BCC23E6Q33300609-5031E2C2-4168-4FAD-BD29-B1D43E157A16Q33536143-321B60B8-EC31-4E0E-8042-B29703A7DB48Q33644139-BD1CA515-3AE8-4A3D-909D-E5C181668823Q33918990-6B288A0F-C0E9-4027-9764-B109333FF4E2Q34484441-8754850F-A5C3-4574-A81D-0869A4D92C6AQ35036839-88217FA4-5C7A-4D7C-B7D6-60058ABDD3EEQ35617544-4F8A616C-5E62-4D45-A963-F87EB37A6513Q35686856-908EA1FB-6C7E-4D3C-9140-97239E40ACAFQ35762849-9AAFEF6B-5365-4BE6-A2B7-5E44CAD62A14Q36173758-2B52CC30-E1E0-487B-9A0B-82D3817B13FBQ36274912-5191261B-7779-4EAC-97CF-A8CABF0E77D7Q36626793-64DCA535-3D9E-45CF-A64E-55754C469A85Q36920000-55319F96-34FA-40DC-A075-AB4C718D7191Q37116485-C08CD3D0-9833-4D0F-9595-5C6A5B6DAEF2Q37318853-20D3568E-9659-4678-9E2A-BCFF40324792Q37458863-2CE5ADDF-4945-449B-B5F5-94FA6622DD18Q37531610-2E6FBD8C-A277-4663-BFE4-86551147C862Q38548772-01E9C8A4-2810-4A7F-AD4E-AD0F0C4BD053Q39646062-2FCD0A22-8948-4941-8F60-0B88A60C3966Q42602131-EB43A8C6-24DB-4C3B-9265-C196025A33EBQ42789677-DE6DFE92-0C20-465A-B9A0-D052E66C876AQ43767346-B15D42D8-70D8-4869-86B0-ACAECA260BF3Q43944744-3D31CAB1-C643-4CB6-909C-72D32F85716FQ44563821-9A1FBF73-D2DA-4229-A20B-671D9BF55321Q48021105-4E62C66E-5DEF-411C-A616-6D5ABC572634
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Medical therapy cost considerations for glaucoma.
@ast
Medical therapy cost considerations for glaucoma.
@en
type
label
Medical therapy cost considerations for glaucoma.
@ast
Medical therapy cost considerations for glaucoma.
@en
prefLabel
Medical therapy cost considerations for glaucoma.
@ast
Medical therapy cost considerations for glaucoma.
@en
P2093
P1476
Medical therapy cost considerations for glaucoma.
@en
P2093
Daniel H Patuszynski
Jacob Wilensky
Richard G Fiscella
P356
10.1016/S0002-9394(03)00102-8
P407
P577
2003-07-01T00:00:00Z